Embrace IP disruption or get left behind
The launch of the Unified Patent Court today is the latest development in a revolutionary period that is only just getting started and from which there is no escape
The launch of the Unified Patent Court today is the latest development in a revolutionary period that is only just getting started and from which there is no escape
The diagnostics innovator has bagged a further $100 million in damages, but the country’s patent system has put unnecessary hurdles in the way, argues representative John Desmarais.
As we reveal the agenda for IAM Live: Patent Transactions 2023, we asked patent dealmakers to tell their stories of relationship-building at IP conferences
The chipmaker spawned the term “patent troll” and has been highly critical of NPEs, but negative business headwinds mean that putting its world-class portfolio of IP assets to work is a no brainer
19 August 2022
In an exclusive interview, the company’s CEO Jacob Babcock details its journey to becoming a technology licensing business
16 August 2022
A strategic review that began in December 2021 is ongoing with several options being explored and meanwhile the firm continues to do deals
11 August 2022
The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November
10 August 2022
The portfolio covers a wide range of the tech produced by the Silicon Valley giant and will now be monetised by an entity named Tahoe Research Limited
08 August 2022
The firm is the latest in a string of big-ticket licensors to have published their quarterly earnings, following Ericsson, Nokia and Qualcomm
05 August 2022
New amendments encompass 40 new articles, alongside revisions to 41 others. They aim to enhance protection of trade secrets and strengthen communications between the IP Court and the IP Office, among other goals.
03 August 2022
Marianne Frydenlund joins the firm from Nordic Semicondustor with a brief to develop solutions for IoT-related sectors beyond auto
01 August 2022
The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months
29 July 2022
CEO Christiano Amon hails “a significant milestone event” that validates the power of the company’s portfolio and innovation
28 July 2022
Unlock unlimited access to all IAM content